Semin Thromb Hemost 2019; 45(04): 321-325
DOI: 10.1055/s-0039-1688494
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update

Anjlee Mahajan
1   Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, California
2   Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California
,
Ann Brunson
2   Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California
,
Richard White
2   Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California
3   Division of General Internal Medicine, UC Davis School of Medicine, Sacramento, California
,
Ted Wun
1   Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, California
2   Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California
4   Clinical and Translational Sciences Center (CTSC), UC Davis School of Medicine, Sacramento, California
› Author Affiliations
Further Information

Publication History

Publication Date:
30 April 2019 (online)

Preview

Abstract

The incidence of venous thromboembolism (VTE) is known to be higher in patients with malignancy as compared with the general population. It is important to understand and review the epidemiology of VTE in cancer patients because it has implications regarding treatment and prognosis. Multiple studies have shown that cancer patients who develop VTE are at higher risk for mortality. This article will focus on an update regarding the epidemiology of cancer-associated thrombosis (CT). The authors will describe factors associated with CT risk including cancer type and stage at the time of diagnosis, race and ethnicity, and cancer-directed therapy. In addition, recurrent thrombosis and the effect of thromboembolism on survival in cancer patients will also be addressed.